三阴性乳腺癌组织耐药蛋白GST-π和LRP及TopoⅡ表达的研究  

Expressions and clinical significance of GST-π,LRP and TopoⅡ in triple negative breast cancer tissues

作　　者：桑晶[1] 韩玉贞[1] 张志强[1] 吕增华[2] 朱玉红[2] 

机构地区：[1]滨州医学院病理教研室,山东滨州256603 [2]滨州医学院附属医院病理科,山东滨州256603

出　　处：《中华肿瘤防治杂志》2011年第7期521-523,共3页Chinese Journal of Cancer Prevention and Treatment

基　　金：山东省医药卫生科技计划基金资助(2009HZ-001)

摘　　要：目的:探讨耐药蛋白GST-π和LRP与TopoⅡ在三阴性乳腺癌组织中的表达及其临床意义。方法:选取术前未行化疗和内分泌治疗的乳腺癌标本252例,利用免疫组织化学方法对ER、PR和HER-2蛋白表达进行检测,根据结果将其分为三阴性乳腺癌和非三阴性乳腺癌,分别检测耐药蛋白GST-π、LRP与TopoⅡ在两组内的表达水平。结果:18.7%(47/252)的病例为三阴性乳腺癌,其耐药蛋白GST-π的表达水平明显高于非三阴性乳腺癌(χ2=10.466,P=0.001),而LRP与TopoⅡ的表达水平在两组之间差异无统计学意义,P值分别为0.678和0.777。结论:与乳腺癌其他亚型相比,三阴性乳腺癌具有更强的耐药性,而药蛋白GST-π高表达可能是其耐药的重要因素之一。OBJECTIVE： To explore the expressions of GST-π, LRP and Topo Ⅱ in triple negative breast cancer, and study their clinical significance. METHODS; Totally 252 breast cancer patients without preoperative chemotherapy and endocrine therapy were divided into TNBC （triple negative breast cancer） group and the non-TNBC （non-triple-negative breast cancer） group according to the expression of ER, PR and HER-2. The expres sions of GST-re, LRP and Topo~ were investigated using the immunohisto chemistry method in above two groups. RESULTS： Of all breast cancer patients 18. 7% （47/252） were triple negative breast cancer. GST re expression in the TNBC group was significantly higher than that in the non-TNBC group （Х^2=10. 466,P= 0. 001）. No significant differences were found in LRP and TopoⅡ expression between the two groups （P=0.628,P 0.777）. CONCLUSIONS： TNBC has higher drug resistance that other subtypes. High expression of GST-π may play an important role init.

关 键 词：乳腺肿瘤 耐药蛋白 GST-Π LRP TopoⅡ 

分 类 号：R737.9[医药卫生—肿瘤]